title: The changing model of big pharma: impact of key trends.
abstract: Recent years have seen exciting breakthroughs in biomedical sciences that are producing truly novel therapeutics for unmet patient needs. However, the pharmaceutical industry is also facing significant barriers in the form of pricing and reimbursement, continued patent expirations and challenging market dynamics. In this article, we have analyzed data from the 1995-2015 period, on key aspects such as revenue distribution, research units, portfolio mix and emerging markets to identify four key trends that help to understand the change in strategic focus, realignment of R&D footprint, the shift from primary care toward specialty drugs and biologics and the growth of emerging markets as major revenue drivers for big pharma.
authors.affiliation: AsiaPac & Emerging Markets, IMED Biotech Unit, AstraZeneca, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China. Electronic address: ajay.gautam@astrazeneca.com.
authors.forename: Ajay
authors.initials: A
authors.lastname: Gautam
authors.affiliation: AsiaPac & Emerging Markets, IMED Biotech Unit, AstraZeneca, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China.
authors.forename: Xiaogang
authors.initials: X
authors.lastname: Pan
mesh_terms: D001688:Biological Products; D003365:Costs and Cost Analysis; D004345:Drug Industry / Q000639:trends*; D012106:Research
chemical_list: D001688:Biological Products